Ads
related to: Skyrizi- Dosing & Administration
Learn About A Dosing Routine That
Can Fit Your Patients Schedule.
- Getting Patients Started
Find Support Resources
For Your Patients On The HCP Site.
- COSENTYX Injection Info
Learn About Dosing & Device Options
And How To Support Your Patients.
- Clinical Trial Data
View Study Data
And Robust Safety Profile.
- Dosing & Administration
Search results
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease
Zacks via Yahoo Finance· 2 years agoThe FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was...
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication
Zacks via Yahoo Finance· 1 year agoThis week, Merck MRK offered to buy Imago Biosciences IMGO, which is developing drugs to treat bone...
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
Reuters via Yahoo Finance· 3 months ago(Reuters) -AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and...
AbbVie (ABBV) Q2 2022 Earnings Call Transcript
Motley Fool· 2 years agoImage source: The Motley Fool. AbbVie (NYSE: ABBV) Q2 2022 Earnings Call Jul 29, 2022, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call...
Will AbbVie's (ABBV) New Drugs Continue to Drive Q4 Earnings?
Zacks via Yahoo Finance· 1 year agoAbbVie’s ABBV fourth-quarter revenues are likely to be driven by revenues generated from the sales...
AbbVie Beats On Q4 Earnings, Skyrizi Sales Grows 76%, Annual Guidance Lags Consensus
Benzinga via Yahoo Finance· 1 year agoAbbVie Inc (NYSE: ABBV) has reported Q4 adjusted EPS of $3.60, up 16.9% Y/Y and beating the...
AbbVie's Blockbuster Is Falling Fast. Time to Sell?
Motley Fool· 12 months agoLast week wasn't a great one for a lot of pharmaceutical stock investors. Shares of AbbVie (NYSE: ABBV) dropped by about 8% on Thursday, April 27. The...
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 12 months agoAbbVie's (ABBV) Q1 performance will likely reflect declining sales of Humira following the loss of...
AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why
Zacks via Yahoo Finance· 2 years agoAbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S....
Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks
Motley Fool· 2 years agoWith the market down by more than 21% in 2022, we're officially in a bear market, and many investors...
Ads
related to: Skyrizi